Thermo Fisher Scientific and Verici DX Collaborate on Pre-Transplant Assay
Verici Dx signed a licensing agreement with Thermo Fisher on an assay for pre-transplant prognostic testing of early kidney rejection risks.
Read MorePosted by Andy Lundin | Nov 17, 2023 | Transfusion & Transplantation Tests |
Verici Dx signed a licensing agreement with Thermo Fisher on an assay for pre-transplant prognostic testing of early kidney rejection risks.
Read MorePosted by Chris Wolski | Nov 16, 2023 | Diagnostic Technologies |
Consolidation, legislation, new testing types, and a shift to more consumer-driven testing are some clinical laboratory predictions for 2024.
Read MorePosted by Andy Lundin | Oct 18, 2023 | Cancer |
The University of Illinois Chicago will participate in a study of a test that screens for a shared cancer signal in patient blood samples.
Read MorePosted by Andy Lundin | Oct 17, 2023 | Hematology & Serology |
FloBio announced that the U.S. FDA has granted Breakthrough Device Designation for its rapid bleeding risk diagnostic test.
Read MorePosted by Andy Lundin | Oct 16, 2023 | Immunoassay Reagents & test Kits |
Werfen announced 510(k) clearance of Aptiva Connective Tissue Disease (CTD) Essential reagent by the U.S. Food and Drug Administration (FDA).
Read More